Showing posts with label persistence. Show all posts
Showing posts with label persistence. Show all posts

Sunday, 16 January 2011

Secondary database analysis: models for measuring medication adherence and persistence

Secondary database analysis is a common used process to evaluate patients’ drug taking behaviour. There are more standardized models for measuring adherence and persistence.


Medication adherence:
Medication Possession Ratio (MPR):
  • MPR:    number of days of medication supplied within the refill interval / number of days in refill interval
  • At least two fill dates are needed to calculate this ratio.
  • Numerator: total X days of supply
  • Denominator:
    • last refill as the end point 
                        total X days of supply              
last X date – fisrt X date + last X days of supply
    • fixed interval (e.g. seasonal diseases) 
total X days of supply
            fixed interval (X days)
  • Dual or triple therapy (e.g. hypertension): the numerator must be / with 2 or 3
  • MPR is a dichotomous various (adherent / non-adherent).
  • Cut-off value is disease specific.
    • Conventional: patients with adherence over 80% (MPR) can be called adherent.
    • Overuse: MPR is over 1.0 (100%), these patients are also non-adherent !

Proportion of days covered (PDC):
  • PDC: the number of days with all drug(s) on-hand / the number of days in the observation interval.
  • PDC values range from 0 to 1.

MPR vs. PDC : Is the patient adherent?
Drug
Months 1-12
Supply (days)
A
x
x
x
x
x
x



x
x
x
9x30=270
B

x
x
x
x

x
x
x
x


8x30=240
C


x

x

x
x

x
x
x
7x30=210



↑

↑




↑


3x30=90
MPR: ((270+240+210)/3) / 360 = 0.66
PDC: 90 / 360 = 0.25


Medication peristence:
  • The duration of time from the initiation (or at chronic disease from an optional date) to the discontinuation of drug therapy. (Permissible gap: is reported as the maximum allowable period of the refill interval without discontinuation of the therapy.)
  • Percentage of individuals remaining on therapy (persistent) until a specified time interval.
Patients persisted x days vs. y patients were persistent for z days
Patient
Months 1-12
(1 month = 30 days)
Days persistent (gap=30 days) *
Persist 180 days (gap=30 days) **
A
x
x
x
x


x
x
x



120
no
B
x
x
x
x
x
x



x

x
180
yes
C
x
x



x
x


x

x
60
no
*: patients persisted on avarge 120 days ((120+180+60)/3)
**: 33% (1/3) of the patients were persistent for 180 days

References
Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL.Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009 Jan;43(1):36-44.
Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC: Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009 Sep;12(6):989-95.
Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M: A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007 Jan-Feb;10(1):3-12.

 

Sunday, 9 January 2011

Definitions: adherence, compliance, persistence, concordance


The definitions of the patient co-operation are not uniformed. This causes many difficulties when comparing the results of the studies. I searched the net and I found some good summaries about the meaning of adherence, compliance, concordance, persistence etc.
As follows adherence, compliance, persistence are defined based on the classifications of WHO, NICE, ISPOR and ABC.
Adherence: the extent to which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider. 

NICE

Adherence: ‘the extent to which the patient’s behaviour matches agreed recommendations from the prescriber’. Adherence emphasises the need for agreement and that the patient is free to decide whether or not to adhere to the prescriber’s recommendation.
Concordance: this is a recent term whose meaning has changed. It was initially applied to the consultation process in which prescriber and patient agree therapeutic decisions that incorporate their respective views, but now includes patient support in medicine-taking as well as prescribing communication. Concordance reflects social values but does not address medicine-taking and may not lead to improved adherence.
Persistence: The length of time from initiation to discontinuation of therapy.

ISPOR
Medication compliance (synonym: adherence): refers to the degree or extent of conformity to the recommendations about day-to-day treatment by the provider with respect to the timing, dosage, and frequency. It may be defined as “the extent to which a patient acts in accordance with the prescribed interval, and dose of a dosing regimen.”

Medication persistence: refers to the act of continuing the treatment for the prescribed duration. It may be defined as “the duration of time from initiation to discontinuation of therapy.” Persistence analyses must include a prespecified limit on the number of days allowed between refills, considered the “permissible gap.”



Medication adherence: is the process by which patients take their medication as prescribed. It consists of three parts:
Initiation: occurs when the patient takes the first dose of the prescribed medication.
Discontinuation: occurs when the patient stops taking the prescribed medication.
Execution: patients’ accuracy in following the day-to-day dosing regimen while still actively taking the medication. It is the multidimensional outcome of the comparison of two time series: the prescribed drug dosing regimen and the patient’s drug dosing history while he or she is still engaged with treatment. Evaluation is disease/treatment specific.
Persistence: the length of time that the patient continues to be engaged with the prescribed dosing regimen.
Medication adherence is best quantified using two parameters: execution and persistence.
Medication therapy management: The overall process of assisting patients in the initiation and conduct of their drug therapies.
Adherence-Related Behavioral Science: the many disciplines concerned with patients’ and providers’ decision-making, acceptance of, and ability to effectively adhere to a medication regimen.
Pharmionics: The discipline concerned with the quantitative assessment of what patients do with prescribed medicines. It is concerned with the study of how prescribed medications are used by ambulatory patients. Pharmionics (ion=to go) means “the going of the pharmaceutical(s)” and constitutes thus a link to the biomedical field as a natural input to pharmacokinetic and pharmacodynamic models for quantitative analysis of pharmacometric and economic consequences of dosing errors.